BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...

This newly issued patent will strengthen Ocean Biomedical’s intellectual property portfolio and provides protection in one of the world’s largest pharmaceutical markets. The granted claims cover the ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

Ocean Biomedical (OCEA) announced that the China National Intellectual Property Administration has granted a notice of grant on patent right ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...

Bispecific antibodies have gotten plenty of press in recent years, but less prominent in headlines are bifunctional ones – i.e., those that boast one binding site for an antigen and another site for a ...

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...